We hypothesized that a cancer vaccine strategy would provide prolonged efficacy due to T cell immunity, and this report describes the high rate of long term DFS of seven patients with high-risk, resected, HER2 overexpressing breast cancer after immunization with dendritic cell based vaccines loaded with the ICD protein. This evidence concerns the gene ERBB2 and cancer.